By Denny Jacob
Alcon reported topline results from two trials evaluating AR-15512, a candidate treatment for dry-eye disease.
The eye-care company said the primary endpoint achieved statistical significance in both trials. Additional data derived from secondary endpoints demonstrated the rapid onset and sustained tear production, said Alcon.
AR-15512 was well tolerated and no serious ocular adverse events were reported.
Alcon expects to file a new drug application for AR-15512 with the U.S. Food and Drug Administration in mid-2024.
Write to Denny Jacob at [email protected]
Read the full article here
